RxDoctor Payments Data

Katherine Tucker

Family · Nashville, TNNPI 1225474125

Payments from drug & device makers

$1,434in general payments, 2019–2025

Across 52 payments — averaging $27.58 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$402
  • Collegium Pharmaceutical, Inc.$304
  • Boston Scientific$203
  • Bioventus LLC$155
  • Scilex Pharmaceuticals Inc.$100
  • Pacira Pharmaceuticals Incorporated$41
  • plus $229 from 11 others

What the payments were for

  • Food & beverage$1,434100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,434 in reported general payments places this provider in the 70th percentile of 6,706 family providers in Tennessee.

See all family providers in Tennessee

Medicare billing

Part B allowed, 2024
$60,733
Medicare patients
91
Services billed
759

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Xtampza ErOxycodone Myristate80$61,008
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen1,268$44,743
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen922$28,588
Nucynta ErTapentadol Hcl20$23,431
Gabapentin742$9,176
OxycontinOxycodone Hcl16$7,506
Lidocaine65$7,440
LyricaPregabalin11$6,282
Diclofenac Sodium286$4,536
Pregabalin236$4,285
Tizanidine Hcl418$3,893
Morphine Sulfate ErMorphine Sulfate169$3,038
Cyclobenzaprine Hcl216$2,891
Oxycodone Hcl164$2,573
Celecoxib57$1,848

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Collegium Pharmaceutical, Inc.Xtampza Er, Nucynta Er$304$84,439100 claims
Hikma Pharmaceuticals USAMorphine Sulfate$19$22618 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 6,706 family providers in Tennessee.

Other family in Nashville

See the full list for Tennessee

Where these figures come from

Is this you, or does something look wrong? →